In Vitro Activity of a New Antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae
AUTOR(ES)
Roblin, Patricia M.
FONTE
American Society for Microbiology
RESUMO
The in vitro activity of NVP-PDF386 (VRC4887), a novel new peptide deformylase inhibitor, and those of levofloxacin and clarithromycin were tested against 21 isolates of Chlamydia pneumoniae. The MIC at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by NVP-PDF386 for all isolates of C. pneumoniae were 0.008 μg/ml (range, 0.008 to 0.015 μg/ml) compared to 0.25 and 0.06 μg/ml for levofloxacin and clarithromycin, respectively.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=152502Documentos Relacionados
- In Vitro Activity of ABT 773, a New Ketolide Antibiotic, against Chlamydia pneumoniae
- In Vitro Activity of a New Ketolide Antibiotic, HMR 3647, against Chlamydia pneumoniae
- In Vitro Activity of Tebipenem, a New Oral Carbapenem Antibiotic, against Penicillin-Nonsusceptible Streptococcus pneumoniae
- In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia.
- In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.
